Mycophenolate Mofetil in Myasthenia Gravis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
This is a prospective, multi-center, double-blind, placebo-controlled trial to determine the efficacy and safety of mycophenolate mofetil (MM) in combination with prednisone as the initial form of immunosuppression in patients with acquired myasthenia gravis (MG).
Condition | Intervention | Phase |
---|---|---|
Myasthenia Gravis |
Drug: mycophenolate mofetil |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
Official Title: | A Trial of Mycophenolate Mofetil in Myasthenia Gravis |
- QMGS
- Multiple
Estimated Enrollment: | 80 |
Study Start Date: | September 2002 |
Study Completion Date: | March 2007 |
80 patients with seropositive MG at 18 academic centers will be randomized to 3 months of treatment with 2.5 gm MM/day (1,250 mg q 12 hours, +/- 2 hours) plus 20 mg prednisone/day versus placebo plus 20 mg/day prednisone. The primary measure of efficacy will be the change from baseline in Quantitative MG (QMG) score at the end of 3 months. Secondary outcome measures include survival analysis for treatment failure, MG-related impairment of daily activities, functional assessment, manual muscle testing, SF-36 Health Status, and serum concentration of antibodies to the acetylcholine receptor. Study completers will have the option of taking open-label MM for an additional 6 months, during which prednisone will be reduced to the lowest dose necessary to maintain the optimum clinical response.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria
Acquired generalized MG diagnosed by one of the Principal Investigators based on:
- Examination by site PI showing myasthenic weakness that is not limited to the ocular or peri-ocular muscles.
- Elevated acetylcholine receptor antibodies.
- Positive edrophonium chloride test or abnormal neuromuscular transmission demonstrated by single fiber EMG or repetitive nerve stimulation.
- Aged at least 18.
- Able to give informed consent.
- Taking a constant dose of Mestinon for at least 2 weeks.
- Symptom severity that would, in the judgment of the site investigator, justify initiation of immunosuppressive treatment.
- Able and willing to comply with study requirements.
Exclusion criteria
- Thymoma now or in the past.
- Plasma exchange or IVIG treatment within 90 days of randomization.
Treatment with azathioprine, cyclosporine, mycophenolate mofetil, or other immunosuppressive medication since onset of MG. Treatment with prednisone or other corticosteroids within the previous 90 days.
• Exception: patients may have taken doses of these immunosuppressant medications that are judged by the Principal Investigator to have been clinically insignificant, i.e. unlikely to produce improvement in MG.
- Women of childbearing potential who are pregnant, breast-feeding or not practicing effective contraception.
- Renal failure, active thyroid or hepatocellular disease, chronic infection, poorly controlled cardiac disease, or any other illness, including psychiatric disease, that would, in the opinion of the treating physician, make it unsafe for the patient to participate or would interfere with the interpretation of study results.
- Weakness affecting only ocular or peri-ocular muscles (Myasthenia Gravis Foundation of America Class I).
- Severe weakness predominantly affecting oropharyngeal, respiratory muscles or both (MGFA Class IVB).
- Crisis or impending crisis (defined as FVC <10ml/Kg or bulbar weakness severe enough to compromise airway protection.)
- Hemoglobin <10mg/dl; WBC <3,500.
- History of non-compliance with treatment and office visits.
- Thymectomy within 12 months before randomization.
- Concurrent medical condition that would pose an unacceptable risk from immunosuppression, including a positive skin test for tuberculosis (PPD), unless the patient has previously received appropriate treatment.
No publications provided
ClinicalTrials.gov Identifier: | NCT00285350 History of Changes |
Obsolete Identifiers: | NCT00127894 |
Other Study ID Numbers: | 2154 |
Study First Received: | January 31, 2006 |
Last Updated: | April 24, 2007 |
Health Authority: | United States: Food and Drug Administration |
Keywords provided by FDA Office of Orphan Products Development:
myasthenia gravis |
Additional relevant MeSH terms:
Myasthenia Gravis Muscle Weakness Autoimmune Diseases of the Nervous System Nervous System Diseases Neuromuscular Junction Diseases Neuromuscular Diseases Autoimmune Diseases Immune System Diseases Muscular Diseases Musculoskeletal Diseases Neuromuscular Manifestations Neurologic Manifestations Pathologic Processes |
Signs and Symptoms Mycophenolate mofetil Mycophenolic Acid Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on October 16, 2012